BACE inhibitor

This page shows the latest BACE inhibitor news and features for those working in and with pharma, biotech and healthcare.

Eisai to tackle dementia in new US research facility

Merck &Co has also seen failure with its BACE1 inhibitor verubecestat, which also led to the drug’s abandonment. ... However Eisai, which also has a BACE inhibitor elenbecestat in late-stage testing, has several dementia candidates in its pipeline, and

Latest news

Daily Brief: PRIME status for vaccine, NHS urged to adopt automation, Brexit votes loom

Today’s biggest pharma news is more grim tidings from the field of Alzheimer’s research – AZ and Lilly have conceded defeat on their BACE inhibitor. ... Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat.
Merck BACE inhibitor adds to litany of Alzheimer's trial failures

The latest disappointment comes from a phase II/III study of Merck &Co's BACE inhibitor verubecestat, a drug designed to block the formation of the amyloid plaques that are a ... verubecestat. Merck (known as MSD outside the US and Canada) is currently
Biogen rises on more positive data for Alzheimer's candidate

compounds. . Last week, it partnered with AstraZeneca (AZ) on MEDI1814, an antibody against amyloid-beta 42 (Aβ42) in phase I trials, and is also working with AZ on BACE inhibitor AZD3293,
Lilly taps AstraZeneca for another anti-amyloid drug

The two companies are already working together on AZD3293, a BACE inhibitor which is designed to interrupt the formation of Aβ at an early stage in the process, and are running ... secretase inhibitor semagacestat.
Lilly sinks as solanezumab fails again in Alzheimer's

trial in 'prodromal' patient's in the earliest stages of the disease due to report results in 2021 – as well as other pipeline projects such as its AstraZeneca-partnered BACE inhibitor ... Antibodies that directly target amyloid, small-molecule BACE

More from news
Approximately 2 fully matching, plus 19 partially matching documents found.

Latest Intelligence

Deal Watch table for September 2014

525. AstraZeneca / Lilly. Licence and collaboration. Oral BACE inhibitor in phase I for Alzheimer's disease. ... TGR-1202 an oral P13K-delta inhibitor in phase II for haematological malignancies.
Pharma deals during September 2014

Rhizen to change their deal from a 50/50 joint venture to a global (excluding India) licence. The product, an oral PK13 delta inhibitor appears to have completed phase 2 the ... AstraZeneca and Lilly have announced a joint development and
Eisai: Bucking the trend with R&D growth

BACE inhibitor E2609.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Senior Medical Writer: Salary TBC

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Global Business Development Director – Health Education: excellent commission

Account Director – Healthcare Marketing – Berks: Salary TBC

Medical Writer: Salary TBC

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Account Director, Medical Education: Salary TBC

Senior Account Director development role to Business Director, H...: Excellent package

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Account Director, Healthcare Marketing Agency: Salary TBC

Client Services Director – Medical Education Agency – North West...: Salary TBC

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Account Director – Health Policy – Global Agency: Salary TBC

Account Manager / Account Director: Competative

Account Manager / Senior Account Manager: 35, 000-40, 000

Associate Director: £75, 000-90, 000

Subscribe to our email news alerts

PMHub

Add my company

Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Unlocking the potential of science and technology in the UK: Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints: What to expect from 2019...
Not another weight-loss ad: Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...